自体造血干细胞移植后幸存者多年后仍存在疫苗可预防疾病的体液免疫缺陷
研究测量了56例未完成常规疫苗接种计划的自体造血干细胞移植患者(中位移植后7年)的抗体滴度,发现几乎所有人对白喉(98.2%)和肺炎球菌(100%)抗体不足,34.5%对麻疹抗体不足;随后按指南接种者多能产生足够血清学应答,提示应开展补种。
要点
- 自体HSCT后多年未完成常规疫苗接种者普遍缺乏白喉和肺炎球菌抗体。
- 约三分之一患者对麻疹抗体不足,存在疫苗可预防感染风险。
- 按指南补种后多数患者可产生足够血清学应答,补种仍有价值。
核心结论
- 自体HSCT后未完成常规疫苗接种者多年后仍普遍存在对白喉和肺炎球菌的体液免疫缺陷,部分对麻疹免疫不足。
- 对未完成常规疫苗接种的自体HSCT幸存者,多年后按指南补种仍可产生足够血清学应答。
研究设计与样本
- 研究纳入56例自体HSCT后未完成常规疫苗接种计划的患者,中位移植后7年(范围0-29年),测量抗体滴度。
- 对后续按现有指南接种者评估血清学应答。
主要发现
- 几乎全部参与者对白喉(98.2%)和肺炎球菌感染(100%)抗体滴度不足。
- 显著比例参与者对麻疹(34.5%)抗体滴度不足。
- 后续按指南接种者中,许多人产生了足够的血清学应答。
临床怎么用
- 对未完成常规疫苗接种的自体HSCT幸存者,建议采取务实的补种策略。
- 对肺炎球菌和白喉等病原体可考虑普遍接种,对麻疹和水痘带状疱疹病毒等可考虑血清学指导的接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current international guidelines recommend routinely vaccinating haematopoetic stem cell transplant (HSCT) recipients. Despite significant infection-related mortality following autologous HSCT, routine vaccination programmes (RVP) completion is poor. For recovered HSCT recipients, it is uncertain whether catch-up vaccination remains worthwhile years later. To determine potential susceptibility to vaccine preventable infections, we measured antibody titres in 56 patients, a median of 7 years (range 0-29) following autologous HSCT, who had not completed RVP. We found that almost all participants had inadequate titres against diphtheria (98.2%) and pneumococcal infection (100%), and a significant proportion had inadequate titres against measles (34.5%). Of those subsequently vaccinated according to available guidelines, many mounted adequate serological responses. These data suggest a pragmatic catch-up approach for autologous HSCT recipients who have not completed RVP is advisable, with universal vaccination against some pathogens (e.g. Streptococcus pneumoniae and diphtheria) and serologically-guided approaches for others (e.g. measles and varicella zoster virus).
引用
- Colton H, Greenfield DM, Snowden JA, et al. Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant. Vaccine. 2021. PMID: 34294480. doi:10.1016/j.vaccine.2021.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。